Garden City, NY, Jan. 30, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase” or the “Company”), a next generation biotech, genomics, therapeutics and diagnostics company, today reported that Jason Karkus, one of the driving forces behind ProPhase Diagnostics, becomes President of Nebula Genomics, a wholly-owned subsidiary of ProPhase Labs.

纽约花园城，2024年1月30日（环球通讯社）--ProPhase Labs，Inc.（纳斯达克：PRPH）（“ProPhase”或“公司”），一家新一代生物技术、基因组学、治疗学和诊断学公司，今天报道称，Jason Karkus，ProPhase diagnostics背后的驱动力之一，成为Nebula genomics的总裁，Nebula genomics是ProPhase Labs的全资子公司。

Jason Karkus's remarkable journey at ProPhase Diagnostics is marked by his exemplary leadership and business acumen that led to the successful inception and expansion of the Company's Covid laboratory testing venture, generating an impressive $200 million in revenue during 2021 and 2022. This fiscal achievement fueled ProPhase's growth and strategic acquisition of Nebula Genomics.

杰森·卡库斯（JasonKarkus）在前期诊断领域的非凡历程以其卓越的领导力和商业敏锐度为标志，这导致了该公司新型冠状病毒实验室检测业务的成功启动和扩张，在2021年和2022年期间产生了令人印象深刻的2亿美元收入。这一财政成就推动了Nebula Genomics的前期增长和战略收购。

In his new role, Karkus aims to amplify the Nebula Genomics business-to-business operations, as well as its exciting direct-to-consumer Whole Genome Sequencing (WGS) model. This strategic move is in line with ProPhase's evolution from a high complexity molecular Covid testing laboratory to an advanced WGS pioneer.

在他的新角色中，卡库斯旨在扩大星云基因组学的企业对企业运营，以及其令人兴奋的直接对消费者全基因组测序（WGS）模型。这一战略举措符合前期从高复杂性分子新型冠状病毒检测实验室向先进的WGS先驱的发展。

The Company's state-of-the-art WGS lab, featuring four cutting-edge sequencing platforms, including two high-capacity, low cost, WGS machines, sets a precedent in the United States that the Company believes well positions its WGS lab to revolutionize the genomics industry. As ProPhase focuses on its WGS business lines, Karkus’ leadership, energy and vision are expected to be a driving force.

该公司最先进的WGS实验室拥有四个尖端测序平台，包括两台高容量，低成本的WGS机器，在美国开创了一个先例，该公司认为其WGS实验室能够彻底改变基因组学行业。由于前期专注于WGS业务线，卡库斯的领导力、活力和远见有望成为推动因素。

“ProPhase transformed itself from a supplement manufacturer to a leader in the Covid testing space,” said Ted Karkus, CEO of ProPhase Labs. “Jason was directly responsible for developing and managing all of the major business customers for Covid testing. His expertise in sales as well as his operational coordination with all the other dep.

“前期从补充剂制造商转变为新型冠状病毒检测领域的领导者，”前期实验室首席执行官特德·卡库斯（TedKarkus）说。“Jason直接负责开发和管理新型冠状病毒检测的所有主要业务客户。他在销售方面的专业知识以及与所有其他部门的运营协调。